Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023 | 5% CAGR Projection Over the Next Five Years | Technavio

The global CMV therapeutics market will post a CAGR of nearly 5% during the period 2019-2023 (Graphic: Business Wire)

LONDON--()--The global CMV therapeutics market 2019-2023 is expected to post a CAGR of nearly 5% during the forecast period, according to the latest market research report by Technavio.

Congenital CMV virus is prevalent among one out of every 200 new-borns in the US. The CMV virus causes various disorders in the new-borns. Various preventive measures are undertaken to increase the awareness about the disease has resulted in the mandatory screening of newborns. Early diagnosis and treatments have a higher possibility of curing the disease. Many vendors are researching to develop vaccines that can inhibit the progress of the CMV virus. The high prevalence of congenital MCV virus is one of the major drivers for the growth of the global CMV therapeutics market during the forecast period.

This market research report on the global CMV therapeutics market 2019-2023 also provides an analysis of the most critical trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a significant factor that has the potential to significantly impact the market and contribute to its growth or decline.

In this report, Technavio highlights newborn screening as one of the key emerging trends in the global CMV therapeutics market.

Global CMV therapeutics market: Newborn screening

The early treatment for the CMV disease is faster and simpler and prevents the progression of the virus. This reduces the number of deaths and the possibilities of disabilities caused by the disease. So, many countries around the world have mandated newborn screening in hospitals to identify the disease. For instance, the US mandated newborn screening tests in 2008 as part of Newborn Screening Saves Lives Act of 2007. This is one of the key trends that is expected to fuel the growth of global CMV therapeutics market during the forecast period.

“The high prevalence of the disease has urged many vendors to develop advanced prevention and treatment options. Recently, the US FDA approved PREVIMIS therapy by Merck, for the prevention of CMV in adult patients. Helocyte is planning to Triplex during the forecast period for the prevention of CMV. Many such advancements among vendors will significantly contribute to the growth of global CMV therapeutics market”, says an analyst at Technavio.

Global CMV market: Segmentation analysis

This market report segments the global CMV therapeutics market by ROA (oral, parenteral, and others) and geography (Asia, Europe, North America, and ROW).

The North Americas led the market in 2018 with a market share of more than 40%, followed by Europe, Asia, and ROW respectively. The dominance of North America can be attributed to the accelerating growth momentum of the CMV therapeutics market in the region.

Looking for more information on this market? Request for a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

The global CMV therapeutics market will post a CAGR of nearly 5% during the period 2019-2023


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200